In addition, conjugating clinical grade peptides and Neo-STAT precursors enables a rapid and parallelizable manufacturing paradigm for immunotherapeutics capable of addressing neoantigens, multi-epitope combinations to address tumor heterogeneity and mitigate tumor escape and rapid responses to emerging pandemics. The gene discussed is SOAT1; the disease is neoplasm.